Effectiveness of the Epley’s maneuver performed in primary care to treat posterior canal benign paroxysmal positional vertigo: study protocol for a randomized controlled trial by José Ballve Moreno et al.
TRIALS
Ballve Moreno et al. Trials 2014, 15:179
http://www.trialsjournal.com/content/15/1/179STUDY PROTOCOL Open AccessEffectiveness of the Epley’s maneuver performed
in primary care to treat posterior canal benign
paroxysmal positional vertigo: study protocol for
a randomized controlled trial
José Luis Ballve Moreno1*, Ricard Carrillo Muñoz2, Iván Villar Balboa2, Yolanda Rando Matos1,
Olga Lucia Arias Agudelo1, Asha Vasudeva1, Olga Bigas Aguilera2, Jesús Almeda Ortega3, Alicia Capella Guillén1,
Clara Johanna Buitrago Olaya1, Xavier Monteverde Curto1, Estrella Rodero Perez1, Carles Rubio Ripollès1,
Pamela Catalina Sepulveda Palacios2, Noemí Moreno Farres1, Anabella María Hernández Sánchez4,
Carlos Martin Cantera5 and Rafael Azagra Ledesma6Abstract
Background: Vertigo is a common medical condition with a broad spectrum of diagnoses which requires an
integrated approach to patients through a structured clinical interview and physical examination. The main cause of
vertigo in primary care is benign paroxysmal positional vertigo (BPPV), which should be confirmed by a positive
D-H positional test and treated with repositioning maneuvers. The objective of this study is to evaluate the
effectiveness of Epley’s maneuver performed by general practitioners (GPs) in the treatment of BPPV.
Methods/Design: This study is a randomized clinical trial conducted in the primary care setting. The study’s scope
will include two urban primary care centers which provide care for approximately 49,400 patients. All patients
attending these two primary care centers, who are newly diagnosed with benign paroxysmal positional vertigo, will
be invited to participate in the study and will be randomly assigned either to the treatment group (Epley’s
maneuver) or to the control group (a sham maneuver). Both groups will receive betahistine. Outcome variables
will be: response to the D-H test, patients’ report on presence or absence of vertigo during the previous week
(dichotomous variable: yes/no), intensity of vertigo symptoms on a Likert-type scale in the previous week, total
score on the Dizziness Handicap Inventory (DHI) and quantity of betahistine taken.
We will use descriptive statistics of all variables collected. Groups will be compared using the intent-to-treat
approach and either parametric or nonparametric tests, depending on the nature and distribution of the variables.
Chi-square test or Fisher’s exact test will be conducted to compare categorical measures and Student’s t-test or
Mann–Whitney U-test will be used for intergroup comparison variables.
Discussion: Positive results from our study will highlight that treatment of benign paroxysmal positional vertigo
can be performed by trained general practitioners (GPs) and, therefore, its widespread practice may contribute to
improve the quality of life of BPPV patients.
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Dizziness, a common complaint in patients presenting to
the primary care office and the emergency department, is
a disorder of spatial orientation. Approximately 3% of the
visits to US emergency departments were accounted for
by dizziness presentations according to data from a na-
tionally representative study [1].
Vertigo is a subtype of dizziness, defined as an illusion
of motion caused by a mismatch of information from
the visual, vestibular and proprioceptive systems. Vertigo
is divided into central and peripheral causes. Central ver-
tigo is generally more serious, whereas peripheral vertigo
is usually benign. It has been estimated that 45 to 54% of
the patients who attend the primary care physician with
dizziness are suffering from vertigo [2]. The three most
common causes of vertigo (accounting for 93% of all pa-
tient presentations) are: acute peripheral vestibulopathy
(vestibular neuritis and labyrinthitis), Ménière’s disease
and benign paroxysmal positional vertigo (BPPV), the lat-
ter being the most frequent [3].
The mean age of onset of BPPV is 49 years, its lifetime
prevalence is approximately 2.4%, and its cumulative in-
cidence reaches almost 10% at the age of 80 years [4].
The theories that try to explain the pathophysiology of
BPPV are based on clinical and histopathologic findings.
BPPV occurs as a result of displaced otoconia, which are
small calcium particles (otoliths), normally attached to the
otolithic membrane in the utricle. Because of trauma, in-
fection, aging, and even without any known cause, otoliths
can detach from the utricle and collect within the semicir-
cular canals [5]. The posterior canal is the most frequently
affected of the three semicircular canals. Movement of the
head causes these otoliths to inappropriately trigger the
receptors in the semicircular canals and send false signals
to the brain, causing vertigo and nystagmus, as occurs
during the Dix-Hallpike (D-H) maneuver.
The diagnostic approach to vertigo relies on the qual-
ity of symptoms reported. Patients suffering from vertigo
may be diagnosed by asking the following question: ‘When
you are dizzy, do you have a sense that you or your
surroundings are spinning or moving?’ An affirmative re-
sponse makes the diagnosis of vertigo most likely and di-
rects the physician towards a subsequent search for
vestibular causes. In the case of BPPV, patients may also
present with lightheadedness, unsteadiness, loss of bal-
ance, blurred vision, nausea and vomiting, without hearing
loss or tinnitus. Abnormal rhythmic eye movements (nys-
tagmus) usually accompany the symptoms of BPPV. Signs
and symptoms may come and go, with symptoms fre-
quently lasting from 10 to 30 seconds. Some patients,
however, may feel vertiginous for several minutes and the
imbalance and nausea may last several hours. The average
duration of each episode is two weeks but a third of
patients refer episodes longer than a month. Forty-fourpercent of BPPV cases experience a single episode of dizzi-
ness while 56% are recurrent [4]. Activities that bring
about the signs and symptoms of BPPV can vary from per-
son to person, but are almost always brought on by a
change in the position of the head: turning in bed, neck
extension and tilting the head forward. Although rare, it is
possible to have BPPV in both ears (bilateral BPPV).
Physical examination is the next and the last step to
make an accurate diagnosis. The equipment needed for
the physical examination is simple and available in every
primary care examination room: stethoscope, otoscope,
sphygmomanometer, reflex hammer, tuning fork and a
flat examining bed. Coupled with the medical history and
physical examination, the Hallpike maneuver (also known
as Dix-Hallpike test or) is extensively used in both the
diagnosis and short- and long-term control of BPPV. The
maneuver is performed on a flat examination table. While
the patient is in a seated position, the physician turns the
patient’s head 45° to one side, then rapidly, but smoothly
lays the patient into a supine position with the head hang-
ing about 20° over the end of the table and observes the
patient’s eyes for approximately 30 seconds. The man-
euver is repeated with the head turned to the opposite
side. The result is positive if the patient develops symp-
toms (vertigo) and nystagmus. It has a positive predict-
ive value of 83% and a negative predictive value of 52%
[3] (Additional file 1: Video 1 Dix-Hallpike maneuver).
Most patients with vertigo have benign disorders and
can be successfully managed by the primary care phys-
ician. A low percentage of the disorders require laboratory
testing, advanced testing or referral to a specialist [6].
Treatment options include watchful waiting, vestibulo-
suppressant medication, vestibular rehabilitation, cana-
lith repositioning and surgery. Among these treatment
modalities, canalith repositioning procedures (CRPs) are
the first choice treatment for BPPV. The aim of CRPs is
to move the displaced otoliths from the semicircular
canal back to the utricle where they belong. Another less
effective treatment and more time consuming technique,
the Brandt-Daroff exercise, consists of lying down on your
side and then getting up quickly. The presumed mechan-
ism for this therapy is to loose and disperse particles from
the cupula of the posterior semicircular canal. The aim of
this exercise is habituation and compensation of the ves-
tibular system; it does not prevent recurrence and is not
always well tolerated.
Out of all the CRPs, the Epley’s maneuver has been
the most successfully used, and is particularly indicated
in the treatment of posterior canal BPPV. It consists of a
series of four quick movements of the head and body
from sitting to lying, rolling over, and back to sitting. Each
position is maintained for at least 30 seconds or until
positional nystagmus ceases [7] (Additional file 2: Video 2
Epley’s maneuver). A meta-analysis of three high-quality
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maneuver in short-term follow-up, measured in terms of
the Hallpike test (D-H test) turning negative (odds ratio
(OR) = 5.67; 95% confidence interval (CI) 2.21 to 14.56).
This meta-analysis concludes that further research in this
field should consider the following criteria: 1. The use of a
rigorous randomization technique with respect to ad-
equate pre-allocation concealment; 2. The blinding of
outcome assessors; 3. The inclusion of a post treatment
Hallpike maneuver as a part of the reported results; and
4. Long-term follow-up of patients [8]. Another meta-
analysis came to the same conclusions [9]. Little evi-
dence exists to demonstrate any benefit of the Epley’s
maneuver in long-term follow-up [10].
This maneuver has proved to be useful in both
pediatric [11] and older-aged patients [12] and appears
to be safe and effective if the following few contraindi-
cations are considered: cervical spinal stenosis, severe
kyphoscoliosis, limited cervical mobility, Down syn-
drome, advanced rheumatoid arthritis, cervical radicu-
lopathies, Paget’s disease, morbid obesity, ankylosing
spondylitis, severe lumbar dysfunction and spinal cord
injuries. No serious adverse effects have been reported.
The Epley’s maneuver can be performed by general
practitioners (GPs). Although most clinical trials on the
effectiveness of this maneuver have taken place in spe-
cialized clinics, one study conducted in a primary care
center demonstrated that trained GPs achieved the same
results as the specialists in terms of D-H test turning
negative. However, this study could not prove the sub-
jective improvement of the patients compared to the
control group [13].
Several authors emphasize the need for more research
to be performed in the primary care setting. One article
regrets the slow implementation of the results of scien-
tific evidence, highlighting that in Germany only 8% of
patients are treated with repositioning maneuvers, and
recommending the practice of the D-H and Epley’s ma-
neuvers to these physicians [14]. A study in Israel dem-
onstrated that only 25% of patients with BPPV referred
to a specialist had been correctly diagnosed by their doc-
tors and that in most cases, the correct diagnosis had
been made by otolaryngologists (ENT specialists). Out of
the 120 patients studied, only 2 cases (the 2 submitted
by ENT specialists) had undergone the D-H maneuver
to reach the diagnosis [15]. A study conducted in Spain
found that the average duration between the onset of
symptoms and initiation of treatment with canalith repo-
sitioning maneuvers in a specialized ENT center was
20 weeks and that only 1 patient out of 60 was correctly
diagnosed as BPPV [16]. Moreover, the duration of the
illness before receiving Epley’s maneuver was considered
the only independent predictor of recurrence according
to a long-term follow-up study. A systematic review alsorecommends that more research be performed and em-
phasizes that such investigation should include different
specialists, other than otolaryngologists or neurologists,
such as GPs [17].
Therapy with betahistine dihydrochloride has been widely
prescribed in patients with vestibular disorders for symp-
tomatic treatment of vertigo, and especially in Ménière’s
disease patients. A meta-analysis undertaken to evaluate
the efficacy of betahistine in the treatment of other vertigin-
ous syndromes, such as BPPV (cupulo-canalilithiasis), ana-
lyzed seven double-blind, placebo-controlled, randomized
studies, and confirmed betahistine’s therapeutic benefit and
effectiveness [18]. Several other studies have proved that
the combination of betahistine and repositioning maneu-
vers improve outcomes, in comparison to maneuvers alone
[19,20] but its use for BPPV remains controversial [21].
To date, no relevant studies have been performed on
the impact of the use of the Epley’s maneuver in primary
care settings, in terms of temporary disability (number
of episodes and duration), duration of the drug treat-
ment with its subsequent side effects, referral to special-
ists, number of recurrences and quality of life.
Our clinical trial will be conducted in a primary care
setting, and will study the condition at its earliest stages,
when patients are more likely to attend our practices,
and where the literature is less conclusive. In addition,
response to treatment will be evaluated at one month
and at one year after inclusion in the study. The effective-
ness of the Epley’s maneuver in the remission of symp-
toms during the first week may reduce the course of
vertigo, and may result in improvement of quality of life,
temporary disability and decrease in the amount of medi-
cation taken.Methods/design
Hypothesis
The Epley’s repositioning maneuver, performed by GPs,
is effective in the short, mid and long term for the treat-
ment of BPPV. We expect to find a significant difference
of 30% or over in the negativization of the D-H test in
the intervention group (Epley’s maneuver) compared to
the control group (a sham maneuver), as well as in the
clinical improvement of the patients.Aim
Primary objective
The study’s primary objective is to determine whether the
intervention group (Epley’s repositioning maneuver) im-
proves clinically as compared to the control group (a sham
maneuver), after a week, a month and a year of follow-up
(second, third and fourth visit respectively). Definition of
clinical improvement will include negativization of the
D-H maneuver, improvement in the subjective perception
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that the patients report to have taken.
Secondary objectives
We will analyze whether there is a statistically significant
clinical improvement in the intervention group in com-
parison to the control group in terms of:
1. Negativization of the D-H test at a week, a month
and a year follow-up.
2. Answer to the dichotomous (yes/no) question
regarding presence of vertigo in the previous week.
3. Number of new episodes of vertigo between medical
visits.
4. Time from the baseline visit to the first new episode.
5. Rate of vertigo severity on a 10 point-Likert scale:
0 = no symptoms of vertigo; 10 =most severe and
unbearable.
6. Quality of life measured with the specific
questionnaire Dizziness Handicap Inventory- Short
form (DHI-S).
7. Amount of betahistine tablets taken, according to
the patients’ self-registers.
8. Days of temporary disability due to vertigo or other
causes, recorded on the electronic medical record.
Design
This is a controlled randomized clinical trial, which will
be conducted by GPs who will have previously received
a two-hour training to perform the repositioning maneu-
vers under the supervision of an ENT specialist. Patients
will be reassessed one week, one month, and one year
after the first visit by a different GP from the one who
performed the first visit, in order to accomplish blinding
of both study participants and personnel.
Study’s scope
Two urban primary care centers which provide care for
a population of approximately 49,400 people.
Study sample
All patients with newly diagnosed BPPV, who attend our
two primary care centers, will be potential participants
in our clinical trial. Patients will be systematically re-
cruited with the collaboration of the 26 GPs who work
at the two participant primary care centers. Regardless
the initial cause for the visit, if a GP suspects BPPV, he/
she will check whether the patient meets the inclusion
criteria and presents no exclusion criteria. Eligible par-
ticipants will be informed of the possibility to take part
in the trial and will be supplied with written information
about the study. Those who accept to participate in the
study will be given an appointment for the baseline visit,
preferably within a week and no longer than ten daysafter. The recruitment period is expected to last two
years (Figure 1).
Inclusion criteria
Patients aged 18 years and older who attend our pri-
mary care centers, with suspected diagnosis of BPPV,
and present vertigo or nystagmus following the D-H
maneuver. All other causes of vertigo should be ruled
out through clinical history assessment and review of
the electronic medical record. Written informed con-
sent will be obtained from all subjects, of both the inter-
vention group and the control group, prior to their
inclusion in the study.
Exclusion criteria
The exclusion criteria, which will be detected through
the clinical history, physical examination and review of
the electronic medical record, are:
1. Previous or current diagnoses of labyrinthine
diseases such as Ménière’s disease, labyrinthitis or
vestibular neuronitis.
2. Contraindications to canalith repositioning
procedures: cervical spinal stenosis, severe
kyphoscoliosis, limited cervical mobility, Down
syndrome, advanced rheumatoid arthritis, cervical
radiculopathies, Paget’s disease, morbid obesity,
ankylosing spondylitis, severe lumbar dysfunction
and spinal cord injuries.
3. Pregnancy or breastfeeding.
4. Contraindications to betahistine administration.
5. Patient refusal to participate in the study.
6. Non-residence in the study area.
7. Other causes which may hinder the understanding
of the objectives and methodology of the trial
(language, low educational level, and so on).
Sample size
Accepting an alpha risk of 0.05 and a beta risk of 0.2 in
a bilateral contrast, sample size calculations determined
a need for approximately 75 subjects in each group (the
intervention group and the control group), in order to
detect a statistically significant difference in the im-
provement rate between the two groups (30% for the
control group and 55% for the intervention group) at
follow-up. We estimated a 20% rate of loss in partici-
pants (objectives 1 and 2). This sample size also enables
us to evaluate 1-point clinical improvement in the inter-
vention group compared to the control group, assuming
a standard deviation of 1.9 (objectives 3,5,6,7 and 8). We
estimated a recurrence hazard ratio of 0.5 in the inter-
vention group, assuming that 30% of patients in the
control group will have relapsed after one year. The soft-
ware used for the calculation was GRANMO version
Figure 1 Flow diagram of the study.
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version 7.12 (Program of Research in Inflammatory and
Cardiovascular Disorders. Institut Municipal d’Investiga-
ció Mèdica, Barcelona, Spain).
Randomization
All the relevant information will be presented again to
the participants at the baseline visit and the opportunity
to ask any questions they may deem appropriate will be
offered. After signing the informed consent, inclusion
and exclusion criteria will be reviewed again and BPPV
will be confirmed by the clinical history and physical
examination (D-H test positive to the right or the left) at
the first visit of the study. Those who meet the following
three criteria: presenting no exclusion criteria, all inclu-
sion criteria met, and signed informed consent, will be
randomized to the intervention group or the control
group. Potential participants who fail to comply with the
previous three criteria will be declared ‘screening error’.
Patients will be assigned to the intervention or control
group using the randomization sequence list prepared in
advance by the study statistician. The responsibility for
guarding and supervising the randomization list will rest
on a staff member of our primary care center who is not
directly involved in the trial. GPs will contact the
randomization list guardian by telephone in order to find
out the randomization number and to which study arm
the participant has been assigned. These data will not be
recorded in either the case report forms or in the data-
base. Only the study statistician will be allowed access to
this information. Follow-up visits will be carried out by a
different GP from the one who performed the first visit in
order to accomplish blinding of both study participants
and personnel. The randomization software used will be
‘R: A language and environment for statistical computing’,
version 2.14.2 (R Foundation for Statistical Computing,
Vienna, Austria).
Interventions
A paper case report form (CRF) has been designed to
record all the data from the four visits performed during
the trial. Once completed, the CRF will be submitted to
the study’s coordinator to enable data introduction in
the corresponding database for subsequent analysis. The
paper case report form will be reviewed after a pilot test.
Visit 1: Information and data collection from all
participants
All participants will have their electronic medical record
reviewed. An accurate medical history will be obtained
and a thorough physical examination will be performed.
The information collected will include: age, sex, educa-
tional level, profession and employment status, date of
onset and duration of the symptoms from onset to visit1, previous history of BPPV episodes (total number), past
medical history of other conditions (viral infection in the
previous four weeks, head trauma, neck osteoarthritis or
neck pain), pharmacological treatment, specially for the
treatment of anxiety, depression or hypertension).
During the physical examination we will evaluate blood
pressure in the sitting and standing positions, heart rate,
color of skin and mucous membranes, cardiac and
respiratory auscultation, basic neurological examination
(cranial nerves, visual fields, brainstem and muscle
stretch reflexes, posture, balance and coordination tests
(test station, tests for dyssynergia and dysmetria, and
gait), otoscopy and D-H maneuver to the left and right
to detect the presence of nystagmus or vertigo [22]. If
the examination suggests involvement of the anterior or
lateral semicircular canals or presence of a central ver-
tigo (nystagmus that lasts more than a minute, vertical
nystagmus or alternant), the patient will be excluded
from the study and referred to a specialist.
The results of the D-H maneuver (to the right or left)
will be divided as follows:
1. Negative.
2. Positive. This result will be subdivided into:
a) vertigo with nystagmus or b) vertigo without
nystagmus [23].
The assessment of symptom severity will be performed
using a 10-point Likert scale, ranging from 0 = no symp-
toms of vertigo to 10 =most severe and unbearable.
Assessment of quality of life will be carried out through
the Dizziness Handicap Inventory-Short form (DHI-S),
in an adapted version translated into Spanish by López-
Escamez. The adopted version was validated using the
translation-back translation method by two interpreters
with clinical experience; both translations were then dis-
cussed in a consensus meeting with one of the investiga-
tors, yielding to the adapted version, which presents a
Cronbach’s alpha internal consistency of 0.8014.
The DHI-S is a 10-item self-assessment inventory ef-
fectively used to evaluate the perceived degree of dis-
ability caused by vertigo, dizziness and instability and its
impact on daily life activities. It also identifies physical,
functional, and emotional conditions related to balance
disorders [24].
Visit 1 for patients in the intervention group arm
The Epley’s maneuver will be performed only in the first
visit since a single procedure has been shown to improve
the condition in 76% of patients [25]. Moreover, most
patients may improve spontaneously after a month, re-
gardless of which group they were assigned. The maneu-
ver consists of five sequential positions of the head and
body, performed with the aim to move the displaced
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where they no longer cause symptoms. There is some
controversy over whether postural restrictions for a few
days after this procedure are beneficial for the patient
and can improve outcomes [26]. However, we have de-
cided not to include these restrictions in our study as they
are poorly tolerated and can hamper the comparability be-
tween groups [27].
Visit 1 for patients in the control group arm
A sham maneuver, which will consist of laying the patient
with the head tilted on the affected side for five minutes,
as described in the literature [17,23], will be performed
only on the first visit.
Follow-up visits 2, 3 and 4 to all patients
The second visit will take place 1 week after visit 1. Visits
3 and 4 will be performed 1 month, and 1 year after visit
1, respectively. Telephone reminders will be used to re-
duce patients’ loss during follow-up.
Follow-up visits will include:
 Bilateral D-H maneuver. Outcome measures will be:
nystagmus (yes/no) and vertigo (yes/no).
 Assessment and record of number of new episodes
of vertigo, and time (in days) from the baseline visit
to the first new episode. This information will be
obtained through an accurate medical history, and
review of the patient’s electronic medical record,
including visits to the emergency department, in our
medical centers as well as in other emergency
centers. Outcome measures will be: vertigo (yes/no),
number of episodes, and intensity of symptoms on a
0 to 10-point Likert scale.
 Registration of the total score on the Dizziness
Handicap Inventory-Short form (DHI-S)
 Count of tablets of betahistine taken
 Record of new medication taken, for any cause, from
visit 1
 Registration of days of temporary disability during
the previous year caused by vertigo or any other
cause, in employed participants
 Record of medical consultations due to dizziness.
Statistical analysis
Data will be analyzed in accordance with the CONSORT
guide for cluster randomized trials, and all analyses will
be performed on an intent-to-treat basis [28].
Firstly, the intervention group and control group will
be analyzed for baseline comparability according to the
baseline variables. Descriptive statistics of all studied vari-
ables will be presented in contingency tables. Pearson’s
Chi-square test or Fisher’s exact test will be applied to as-
sess categorical variables. Student’s t-test or ANOVA willbe used if the variables follow a normal distribution and
Mann–Whitney U-test if they do not (objectives 1 and 2).
A multilevel logistic regression analysis will be per-
formed to evaluate the association between the dependent
variable (cured/not cured) and the independent variable
(group assigned), adjusting potential confounders.
A multivariate linear regression model will be con-
ducted to evaluate change in the Likert scale and quality
of life inventory (DHI-S), (objectives 5 and 6); and a Pois-
son or Binomial negative distribution (for of outcome var-
iables in case of over-dispersion) will be used to compare
number of vertigo episodes, number of tablets consumed,
days of temporary disability and days with symptoms (ob-
jectives 3, 7 and 8).
In order to evaluate D-H test’s intra- and inter-observer
variations, corresponding Kappa ponderate indexes (Kp)
and intra-class correlation coefficients (ICC) will be calcu-
lated. Intra-observer variations will be determined through
comparison of the D-H test’s results, performed twice on
each patient, after a five-minute interval, for a total
number of ten patients per observer, in any visit. Inter-
observer variations will be determined through compari-
son of the D-H test’s results on each patient, conducted by
pairs of observers, after a five-minute interval, for a total
number of ten patients per pair of observers, in any visit.
The estimated number of observers will be 10 to 12.
Homogeneity and concordance in the Epley’s maneuver
performance will be evaluated by an expert external
auditor, who will assess between two and three video-
registered maneuvers carried out by each observer.
We will apply the Cox regression model to explore the
effect of the intervention (Epley’s maneuver) on the sur-
vival (that is interval between two vertigo episodes) (ob-
jective 4).
Statistical analysis will be carried out by statisticians
from the Institut Universitari d’Investigació en Atenció
Primària Jordi Gol (IDIAP Jordi Gol), who will have an
advisory role. Data will be introduced into a SPSS ver-
sion 18.0 system database (SPSS Inc, Chicago, IL, USA).
Descriptive analysis, and statistical hypothesis testing,
will also be conducted with the SPSS version 18.0 sys-
tem, with blinding. The level of statistical significance
will be set at 0.05 and all tests will be two-tailed. All
known potential confounding factors will be measured
at the beginning of the study and comparison between
the control and the intervention groups will be carried
out adjusted for these known confounders.
Ethical aspects
The protocol has been reviewed and approved by the
CEIC (Clinical Research Ethics Committee) of IDIAP Jordi
Gol, with the number P12/69. Obtaining a signed in-
formed consent from the participants will be a mandatory
requirement before study initiation. Study information will
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ticipants in the study will have the opportunity to resolve
any doubts about study details. The written consent states
that the study follows the law contained in the Helsinki
Declaration and in Title I, Article 12 of the Royal Spanish
Decree 561/1993 from 16 April 1993.
Data confidentiality: participants will be informed that
data will be treated with absolute confidentiality accord-
ing to the organic law that regulates the confidentiality
of computerized data (Organic law 5/1992), and that data
will be used exclusively for the objectives of the study.Discussion
Our study aims to demonstrate the effectiveness of repo-
sitioning maneuvers in the treatment of posterior canal
BPPV, performed by trained GPs in the primary care set-
ting. We found that only one study had been conducted
in primary care, and it proved that this treatment was ef-
fective in the first week, regarding negativization of D-H
test, but not in terms of subjective improvement of pa-
tients [18]. This study only evaluated patients from base-
line to week 1. In our study we will reassess patients one
week, one month and one year after the first visit.Study limitations
Frentzel glasses (a diagnostic tool to evaluate nystagmus)
were not used in the study in order to achieve a more
realistic approach in the diagnosis of BPPV in primary
care. GPs’ lack of experience in ENT skills may reduce
reliability of the maneuvers but it resembles usual prac-
tice in primary care settings. Therefore, study patients
who only experience vertigo and do not present nystag-
mus during the D-H test will not be excluded from
inclusion (as performed in other studies) [29]. As we
mentioned on the D-H test results section, we will con-
sider both vertigo with nystagmus and vertigo without
nystagmus as positive D-H results; the reason being that
GPs’ lack of experience in ENT skills, and not using the
Frentzel glasses may diminish the D-H test sensitivity
by missing less clear cases of nystagmus. This factor,
however, will be accounted for by evaluating these pa-
tients separately.
Betahistine administration during the course of treat-
ment can speed up the recovery of these patients [25,26]
and may also be useful to evaluate the results of the
study. To avoid bias in our trial, all patients from both
groups (intervention and control), will be prescribed beta-
histine 8 mg on a pro re nata (PRN) basis, up to three
times a day until improvement of symptoms. Each partici-
pant will be given a notebook in order to record the num-
ber of tablets taken between visits. From an ethical point
of view, we believe that leaving patients untreated, apart
from the sham maneuver is an arguable point.The incidence of BPPV may hinder securing an ad-
equate sample size. However, internal data from com-
puterized clinical records indicates that this disorder is
much more frequent than previously reported in the lit-
erature. Moreover, BPPV prevalence increases with age,
reaching 10% in individuals over 80 years old [4].
As this trial evaluates a therapeutic maneuver, the
blinding achieved in this study may not be comparable
to that of a double-blind pharmacological trial. On the
other hand, GPs may present lower skills than experi-
enced ENT specialists, in assessing nystagmus, perform-
ing the D-H test and the Epley’s repositioning maneuver.
Even though some authors support that GPs are quali-
fied to perform these skills [29], this factor will be con-
trolled measuring the inter-observer and intra-observer
variability for each maneuver and evaluation, and includ-
ing ‘observer’ as a potential confounder in a multilevel
logistic regression.
A reduced ability in the performance of Epley’s man-
euver would decrease its effectiveness in our patients,
and may counter to the hypothesis of this trial. Despite
all GPs participating in the trial having been trained in
performing the maneuvers, inclusion of false positive
cases may not be ruled out, with a subsequent decline in
the observed effect.
As in any follow-up study, loss of participants over
time may occur. In order to diminish loss to follow-up,
we will introduce telephone reminders before patient ap-
pointments and will establish contact with their GPs, to
help recruitment if the latter fails.
Strengths of the study
This project aims to improve quality of life in patients
with BPPV by implementing a safe, simple and effective
technique which may avoid unnecessary laboratory tests,
extensive additional testing, referral to specialists and
longer temporary disability.
Due to the lack of use of the D-H test, and Epley’s man-
euver by GPs, most of these patients are not correctly di-
agnosed or treated, [20-22], and consequently suffer from
a longer duration of their symptoms and disability. More-
over, they are frequently treated with drugs, often for long
periods of time, with subsequent unnecessary prolonged
side effects and expense.
Positive results in our study would highlight the sig-
nificance of these techniques in primary care and may
encourage GPs to implement them in their usual prac-
tice. Moreover, they would enable the development of
new guidelines and models for the interoperability be-
tween primary care and ENT specialists.
Trial status
The status of the trial at the time of manuscript submis-
sion is recruiting patients.
Ballve Moreno et al. Trials 2014, 15:179 Page 9 of 10
http://www.trialsjournal.com/content/15/1/179Additional files
Additional file 1: Video 1. Dix-Hallpike maneuver.
Additional file 2: Video 2. Epley’s maneuver.
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